Patents by Inventor Beate Winner

Beate Winner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of TGF-R signaling for treatment of CNS disorders
    Patent number: 8283334
    Abstract: The present invention relates to the use of oligonucleotides for the preparation of a pharmaceutical composition for the prevention or treatment of a disease, wherein neurogenesis and/or neuroregeneration has a beneficial effect, in particular a disease like Morbus Alzheimer, Morbus Parkinson, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophies, Creutzfeldt Jakob Disease, Frontemporal Dementia, Morbus Pick, AIDS Dementia Complex, Vascular Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multisystem-Atrophy, Hallervorden Spatz Disease, Huntington's disease, Stroke, Traumatic Brain and spinal cord Injury, Retinitis Pigmentosa, Macular Degeneration, Glaucoma, Cochlea Degeneration, Depression, Schizophrenia, Multiple Sclerosis, and developmental neurodegeneration.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: October 9, 2012
    Inventors: Ulrich Bogdahn, Ludwig Aigner, Frank-Peter Wachs, Beate Winner, Jurgen Winkler
  • IDENTIFICATION OF NEUROPROTECTIVE AGENTS USING PRO-INFLAMMATORY HUMAN GLIAL CELLS
    Publication number: 20120003655
    Abstract: Provided herein are methods for, inter alia, identifying new therapeutic agents using human cell-based models.
    Type: Application
    Filed: December 3, 2009
    Publication date: January 5, 2012
    Applicant: The Salk Institute for Biological Studies
    Inventors: Maria C.N. Marchetto, Fred H. Gage, Christopher K. Glass, Kaoru Saijo, Beate Winner
  • INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS
    Publication number: 20110263678
    Abstract: The present invention relates to the use of oligonucleotides for the preparation of a pharmaceutical composition for the prevention or treatment of a disease, wherein neurogenesis and/or neuroregeneration has a beneficial effect, in particular a disease like Morbus Alzheimer, Morbus Parkinson, Lewy Body Dementia,—Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophies, Creutzfeldt Jakob Disease, Frontemporal Dementia, Morbus Pick, AIDS Dementia Complex, Vascular Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multisystem-Atrophy, Hallervorden Spatz Disease, Huntington's disease, Stroke, Traumatic Brain and spinal cord Injury, Retinitis Pigmentosa, Macular Degeneration, Glaucoma, Cochlea Degeneration, Depression, Schizophrenia, Multiple Sclerosis, and developmental neurodegeneration.
    Type: Application
    Filed: February 15, 2011
    Publication date: October 27, 2011
    Inventors: ULRICH BOGDAHN, Ludwig Aigner, Frank-Peter Wachs, Beate Winner, Jürgen Winkler
  • Inhibitors of TGF-R-signaling for treatment of CNS disorders
    Patent number: 8022045
    Abstract: The present invention relates to the use of oligonucleotides for the preparation of a pharmaceutical composition for the prevention or treatment of a disease, wherein neurogenesis and/or neuroregeneration has a beneficial effect, in particular a disease like Morbus Alzheimer, Morbus Parkinson, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophies, Creutzfeldt Jakob Disease, Frontemporal Dementia, Morbus Pick, AIDS Dementia Complex, Vascular Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multisystem-Atrophy, Hallervorden Spatz Disease, Huntington's disease, Stroke, Traumatic Brain and spinal cord Injury, Retinitis Pigmentosa, Macular Degeneration, Glaucoma, Cochlea Degeneration, Depression, Schizophrenia, Multiple Sclerosis, and developmental neurodegeneration.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: September 20, 2011
    Inventors: Ulrich Bogdahn, Ludwig Aigner, Frank-Peter Wachs, Beate Winner, Jürgen Winkler